nuv001
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 15, 2023 (NCT05791591)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06133478 | Phase 1 | Nov 27, 2023 | Medpace, Inc., Nuvamid, SFBC Anapharm |
| NCT05791591 | N/A | Apr 15, 2023 | ProRelix Services LLP |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medpace, Inc. | For profit | 1 | 0 | 1 | 2023 |
| Nuvamid | For profit | 1 | 1 | 1 | 2023 |
| ProRelix Services LLP | For profit | 1 | 0 | 1 | 2023 |
| SFBC Anapharm | For profit | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1